z6×ðÁúz6×ðÁú¼¯ÍÅz6×ðÁú¼¯ÍÅz6×ðÁú¼¯Íż¯ÍÅz6×ðÁú¼¯ÍÅz6×ðÁú¼¯ÍÅz6×ðÁú¼¯Íż¯ÍÅ¡¡|¡¡ENGLISH¡¡|¡¡ÉèΪÊ×Ò³¡¡|¡¡¿Í»§²éѯ¡¡|¡¡Á®½à¾Ù±¨¡¡
¾ÉʼìË÷search
z6×ðÁúz6×ðÁú¼¯ÍÅz6×ðÁú¼¯ÍÅz6×ðÁú¼¯Íż¯ÍŹ滮Yinfeng in Chinese
z6×ðÁúz6×ðÁú¼¯ÍÅz6×ðÁú¼¯ÍÅz6×ðÁú¼¯Íż¯ÍÅվȺWeb site group
·áÊ¢£üz6×ðÁúz6×ðÁú¼¯ÍÅz6×ðÁú¼¯ÍÅz6×ðÁú¼¯Íż¯ÍÅÉúÎïz6×ðÁú¼¯ÍÅz6×ðÁú¼¯ÍÅz6×ðÁú¼¯Íż¯ÍŸÉϸ°ûÒ©ÎïµÚ3ÏîIND»ñÅú£¡
·¢²¼¹¤·ò£º2025-01-02 18:30:05 ×÷Õߣº¹ÜÀíÔ± ä¯ÀÀ£º3290´Î


2025ϲ¿ªÐÂÆª£¡¿ÆÑÐÕ÷³ÌÔÙÆ×ÐÂÕ£¡z6×ðÁúz6×ðÁú¼¯ÍÅz6×ðÁú¼¯ÍÅz6×ðÁú¼¯Íż¯ÍÅÉúÎïz6×ðÁú¼¯ÍÅz6×ðÁú¼¯ÍÅz6×ðÁú¼¯Íż¯ÍÅÆë³ϸ°û¹«Ë¾ÂíºØÈ»²©Ê¿ÍŶÓÑз¢µÄ¸Éϸ°ûÒ©ÎYFQLXB-UC01×¢ÉäÒº£©ÔÙ»ñINDÅú¼þ£¡


image.png


´Ë´Î»ñµÃ¡¶¹ú¼ÒÒ©Æ·¼à¶½¹ÜÀí¾ÖÆÀÉóÖÐÐÄ¡·ºË׼ǩ·¢µÄ¸Éϸ°ûÒ©Îï˳Ӧ֢ΪÂý¼Ó¼±ÐÔ¸ÎË¥½ß£¬ÊÜÀíºÅΪ£ºCXSL2400695¡£ÕâÒ²ÊÇz6×ðÁúz6×ðÁú¼¯ÍÅz6×ðÁú¼¯ÍÅz6×ðÁú¼¯Íż¯ÍÅÉúÎïz6×ðÁú¼¯ÍÅz6×ðÁú¼¯ÍÅz6×ðÁú¼¯Íż¯ÍŸÉϸ°ûÒ©ÎYFQLXB-UC01×¢ÉäÒº£©»ñÅúµÄµÚ3ÏîINDÅú¼þ¡£


ÀÛ¼ÆÁÙ´²ÑÐÌÖÒ©ÎïÉ걨ºÍÑÐÌÖÕß·¢ÆðÁÙ´²ÑÐÌÖ18Ï


½üÄêÀ´£¬z6×ðÁúz6×ðÁú¼¯ÍÅz6×ðÁú¼¯ÍÅz6×ðÁú¼¯Íż¯ÍÅÉúÎïz6×ðÁú¼¯ÍÅz6×ðÁú¼¯ÍÅz6×ðÁú¼¯Íż¯ÍÅÔÚϸ°ûÔËÓÃÁìÓò²»¶ÏÉî¸û£¬³ÖÐø¼Ó´óÑз¢´´ÐÂÁ¦¶È£¬ÓëÖÚ¶à¸ßУ¡¢ÔºËùÉî¶È¿ªÕ¹ºÏ×÷½»Á÷¡£Ä¿Ç°z6×ðÁú¼¯ÍÅz6×ðÁú¼¯ÍÅz6×ðÁú¼¯Íż¯ÍÅÄÚÀÛ¼ÆÁÙ´²ÑÐÌÖÒ©ÎïÉ걨ºÍÑÐÌÖÕß·¢ÆðÁÙ´²ÑÐÌÖ18ÏһÏîÆÀ¼ÛYFQLXB-UC01×¢ÉäÒº¾²ÂöÊä×¢ÖÎÁÆÊ§´ú³¥ÆÚ¸ÎÓ²»¯µÄ°²È«ÐÔ¡¢ÄÍÊÜÐÔ¼°ÓÐЧÐÔÁÙ´²ÊµÑé½øÈëIÆÚÁÙ´²¡£

YFQLXB-UC01×¢ÉäÒºÊÇz6×ðÁúz6×ðÁú¼¯ÍÅz6×ðÁú¼¯ÍÅz6×ðÁú¼¯Íż¯ÍÅÉúÎïz6×ðÁú¼¯ÍÅz6×ðÁú¼¯ÍÅz6×ðÁú¼¯Íż¯ÍÅÆë³ϸ°û¹«Ë¾×ÔÖ÷Ñз¢µÄ¶³´æÏ¸°ûÖÆ¼Á£¬¼ä³äÖʸÉϸ°ûÔ´×Ô½¡¿µÖØÉú¶ùµÄÆê´ø×éÖ¯»ªÍ¨ÊϽº£¬ÔÚ¾­¹ýÌåÍâµÄ·ÖÀëÀ©ÔöºóÓëÁÙ´²¼¶¶³´æ±£»¤Òº»ìºÏÖÆ³ÉÁ˸Éϸ°ûÖÆ¼Á£¬Çø±ðÓÚ´«Í³µÄÐÂÓ±ÖÆ¼Á£¬¸Ã¼ÁÐÍÊÇÒ»ÖÖ¡°ÏÖ»õÐÍ¡±µÄ²úÆ·£¬ÇÒ¸´ËÕºóÎÞÐëϴ媼´¿ÉÓÃÓÚ¾²ÂöÊä×¢¡£

´Ë´ÎÐÂ˳Ӧ֢µÄ»ñÅú½øÒ»²½ÍØ¿íÁ˸Éϸ°ûÒ©ÎïµÄÔËÓ÷¶³ë£¬±êÖ¾×Åz6×ðÁúz6×ðÁú¼¯ÍÅz6×ðÁú¼¯ÍÅz6×ðÁú¼¯Íż¯ÍÅÉúÎïz6×ðÁú¼¯ÍÅz6×ðÁú¼¯ÍÅz6×ðÁú¼¯Íż¯ÍÅÔÚ¸Éϸ°ûÒ©Îï×ÔÖ÷Ñз¢´´ÐÂÁìÓòÂõÉÏÁËеĸ߶È¡£½«À´£¬Ëæ×ŸÉϸ°û¼¼ÊõµÄ²»¶Ïz6×ðÁú¼¯ÍźÍÍêÉÆ£¬z6×ðÁúz6×ðÁú¼¯ÍÅz6×ðÁú¼¯ÍÅz6×ðÁú¼¯Íż¯ÍÅÉúÎïz6×ðÁú¼¯ÍÅz6×ðÁú¼¯ÍÅz6×ðÁú¼¯Íż¯ÍŽ«ÔÚ¸Éϸ°ûÒ©ÎïµÄÑз¢ºÍÔËÓ÷½Ãæ»ñµÃ¸ü¶à´òÆÆ£¬Îª¸ü¶àµÄ»¼Õß´øÈ¥¿µ¸´µÄÏ£Íû¡£



ÈËÆê´ø¼ä³äÖʸÉϸ°û×¢ÉäҺ˳Ӧ֢IND»ñÅúÀú³Ì





1



2024Äê3ÔÂ11ÈÕ£¬ÈËÆê´ø¼ä³äÖʸÉϸ°û×¢ÉäÒº£¨´úºÅYFQLXB-UC01£©ÊÕµ½¡¶¹ú¼ÒÒ©Æ·¼à¶½¹ÜÀí¾ÖÖÐÐÄ¡·ºË׼ǩ·¢µÄÎïÁÙ´²ÊµÑéͬÒâ¸æËßÊ飨ÊÜÀíºÅCXSL2300854£©Ë³Ó¦Ö¢ÎªÊ§´ú³¥ÆÚ¸ÎÓ²»¯¡£



2



2024Äê10ÔÂ31ÈÕ£¬ÈËÆê´ø¼ä³äÖʸÉϸ°û×¢ÉäÒº£¨´úºÅYFQLXB-UC01£©ÔÙ´ÎÊÕµ½¡¶¹ú¼ÒÒ©Æ·¼à¶½¹ÜÀí¾ÖÆÀÉóÖÐÐÄ¡·ºË׼ǩ·¢µÄÒ©ÎïÁÙ´²ÊµÑéͬÒâ¸æËßÊ飨ÊÜÀíºÅ£ºCXSL2400516£©£¬Ë³Ó¦Ö¢ÎªÖС¢Öضȼ±ÐÔºôÎü¾½ÆÈ×ÛºÏÕ÷¡£



3



2025Äê1ÔÂ2ÈÕ£¬ÈËÆê´ø¼ä³äÖʸÉϸ°û×¢ÉäÒº£¨´úºÅYFQLXB-UC01£©ÔٴλñµÃ¡¶¹ú¼ÒÒ©Æ·¼à¶½¹ÜÀí¾ÖÆÀÉóÖÐÐÄ¡·ºË׼ǩ·¢µÄÒ©ÎïÁÙ´²ÊµÑéͬÒâ¸æËßÊ飨ÊÜÀíºÅΪ£ºCXSL2400695£©£¬Ë³Ó¦Ö¢ÎªÂý¼Ó¼±ÐÔ¸ÎË¥½ß¡£



¸Éϸ°ûÒ©ÎïÕë¶ÔACLFµÄÓÅÊÆ


YFQLXB-UC01×¢ÉäÒºµÄ´ÎÒªÓÐЧ³É·ÖΪÆê´ø¼ä³äÖʸÉϸ°û£¬¸Éϸ°û¾­¹ý¹é³²Ç¨ÒƵ½¸ÎÔ࣬²¢¾­¹ýÅÔ·ÖÃÚ;¾¶¶ÔËðÉ˲¡Ôî·¢»Ó×éÖ¯ÐÞ¸´ºÍÃâÒßµ÷ÀíµÈ×÷Óá£


°¸ÀýÒ»

¼ä³äÖʸÉϸ°û×÷ΪÐÂÐÍÒ©ÎÔÚACLFÖÎÁÆÖбíÏÖ³ö½Ï´óDZÁ¦¡£ÁÙ´²ÁÆÐ§·½Ã棬´óÁ¿µÄÁÙ´²ÑÐÌÖÊý¾Ý¾ù±íÏÖ³ö½ÏºÃµÄ°²È«ÐÔºÍÓÐЧÐÔ¡£

Íõ¸£ÉúԺʿµÄÒ»Ï·Å±êÇ©¡¢Æ½ÐжÔÕÕ I/II ÆÚʵÑéÖ¤Ã÷Êä×¢ÈËÆê´ø¼ä³äÖʸÉϸ°û¿ÉÒÔÃ÷ÏÔ½µµÍACLF»¼Õß12ÖÜËÀÍöÂÊ£¨·Ö±ðΪ20.8% VS 47.4%£¬P=.015£©[1]¡£


°¸Àý¶þ

À¥Ã÷Ò½¿Æz6×ðÁú¼¯Íŵڶþ¸½ÊôÒ½Ôº¿ªÕ¹µÄÒ»ÏîÓÃÆê´ø¼ä³äÖʸÉϸ°ûÒÆÖ²ÖÎÁÆÑª½¬Öû»ºÍ¶÷Ìæ¿¨Î¤ÖÎÁÆÊ§°ÜµÄÒÒÐ͸ÎÑײ¡¶¾Ïà¹ØµÄÂý¼Ó¼±ÐÔ¸ÎË¥½ßµÄ24¸öÔÂǰհÐÔÑÐÌÖ£¬½á¹û±íÃ÷PEÁªºÏUCMSCÖÎÁÆÃ÷ÏÔ¸ÄÉÆACLF»¼ÕßѪÉú»¯Ä¿±ê¡¢INR¡¢MELDÆÀ·Ö£¬½ø²½ÖÎÁƺó3¸öÔÂÀÛ¼ÆÉú»îÂÊ£¨54.5% vs 29.4 %£¬p=0.015£¼0.05£©ºÍ1ÄêÀÛ¼ÆÉú»îÂÊ£¨54.5% vs 26.5 %£¬p=0.015£¼0.05£©[2]£»


°¸ÀýÈý

ÖÐɽz6×ðÁú¼¯ÍŸ½ÊôµÚÈýÒ½Ôº¿ªÕ¹µÄÒ»ÏîËæ»ú¶ÔÕÕʵÑ飺ͬÖÖÒìÌå¹ÇËèÀ´Ô´µÄ¼ä³äÖÊ»ùÖÊϸ°ûÖÎÁÆÒÒÐ͸ÎÑײ¡¶¾Ïà¹ØµÄÂý¼Ó¼±ÐÔ¸ÎË¥½ß£¬½á¹û±íÃ÷hUC-MSCÁªºÏPE×é¡¢UC-MSC×é¡¢PE×é¡¢³£¹æÖÎÁÆ×é30ÌìÉú»îÂÊ·Ö±ð90%¡¢86.7%¡¢80%¡¢63.3%£¬90ÌìÉú»îÂÊ·Ö±ðΪ65%¡¢50%¡¢56.7%¡¢50%£¬hUC-MSCÁªºÏPE×éÉú»îÂÊ½ÏÆäËû×é¸ü¸ß£¬µ«²îÒìÎÞͳ¼ÆÑ§ÒâÒå[3]¡£

¹ØÓÚÂý¼Ó¼±ÐÔ¸ÎË¥½ß


Âý¼Ó¼±ÐÔ¸ÎË¥½ß£¨acute-on-chronic liver failure£¬ACLF£©ÊÇÖ¸ÔÚÂýÐԸβ¡µÄ»ù´¡ÉÏ·¢ÉúµÄ¼±ÐÔ¸ÎË¥½ß£¬±íÏÖΪ»Æð㣨ѪÇ嵨ºìËØ¡Ý5 mg/dL£©ºÍÄýѪ·Á°­£¨INR¡Ý1.5»òPTA£¼40%£©£¬4ÖÜÄÚ²¢·¢¸¹Ë®ºÍ/»ò¸ÎÐÔÄÔ²¡£¬²¡ÀíÌØÕ÷´ÎÒª±íÏÖΪ¼¤ÁҵIJ»ÊÜ¿ØÖƵÄÈ«ÉíÑ×Ö¢·´Ó¦¡¢ÑǾ޴ó»ò´óÃæ»ý¸Îϸ°û»µËÀ/µòÍö¡¢µ¥Æ÷¹Ù»ò¶àÆ÷¹ÙÁãËéË¥½ß£»Æä90ÌìµÄ²¡ËÀÂʸߴï60%~70%¡£


ACLF³£¹æÖÎÁƲßÂÔ´ÎÒªÓв¡ÒòÒ©ÎïÖÎÁÆ£¨±ÈÈ翹²¡¶¾¡¢¿¹Ï¸¾úÖÎÁÆ¡¢Æ¤ÖÊÀà¹Ì´¼µÈ£©¡¢ÆÕ֧ͨ³ÖÖÎÁÆ£¨±ÈÈçÎÔ´²ÐÝÏ¢¡¢»·¾³Ïû¶¾¡¢Ñª½¬µ°°×Öʹ©¸ø¡¢¶¯Ì¬¼ì²âÑªÆø·ÖÎö¡¢±£¸ÎÒ©ÎïµÈ£©¡¢È˹¤¸ÎÖ§³ÖÁãË飨±ÈÈç·ÇÉúÎïÐÍÈ˹¤¸Î£¬ÉúÎïÐͼ°»ìºÏÐÔÈ˹¤¸Î£©¡¢¸ÎÒÆÖ²ºÍ¸ÎÔÙÉúÖÎÁÆ·½·¨£¨±ÈÈçϸ°ûÒò×ÓIL-22¡¢Á£Ï¸°û¼¯Âä´Ì¼¤Òò×ÓÖÎÁƵȣ©£»ÆäÖиÎÒÆÖ²Îª¶ÀÒ»ÓÐЧµÄÖÎÁÆÊÖÍó¡£µ«ÓÉÓÚ¹©ÌåÆ÷¹Ù¶Ìȱ£¬»¼Õß¿ÉÄÜ»áÔڵȴýºÏÊʵÄÒÆÖ²Æ÷¹Ùʱ²»ÐÒËÀÍö£¬ÇÒ¸ÎÒÆÖ²·ÑÓýϸß¡£Ëæ×ÅÉúÎï¼¼ÊõºÍÔÙÉúҽѧµÄz6×ðÁú¼¯ÍÅ£¬Ï¸°ûÒ©ÎïÖð½¥´Ó¶¯ÎïʵÑéz6×ðÁú¼¯Íŵ½ÔçÆÚÁÙ´²ÊµÑ飬²¢³õ²½ÏÔÏÖÁËÒ»¶¨µÄÖÎÁÆÓÐЧÐÔ£¬ÓÐÍû³ÉΪÖÎÁƸβ¡µÄÐÂÐËÊÖÍó¡£



²Î¿¼ÎÄÏ×


[1]  Shi M, Zhang Z, Xu R, Lin H, Fu J, Zou Z, Zhang A, Shi J, Chen L, Lv S, He W, Geng H, Jin L, Liu Z, Wang FS. Human mesenchymal stem cell transfusion is safe and improves liver function in acute-on-chronic liver failure patients. Stem Cells Transl Med. 2012 Oct;1(10):725-31.

[2]Li YH, Xu Y, Wu HM, Yang J, Yang LH, Yue-Meng W. Umbilical Cord-Derived Mesenchymal Stem Cell Transplantation in Hepatitis B Virus Related Acute-on-Chronic Liver Failure Treated with Plasma Exchange and Entecavir: a 24-Month Prospective Study. Stem Cell Rev Rep. 2016 Dec;12(6):645-653.

[3]Lin BL, Chen JF, Qiu WH, Wang KW, Xie DY, Chen XY, Liu QL, Peng L, Li JG, Mei YY, Weng WZ, Peng YW, Cao HJ, Xie JQ, Xie SB, Xiang AP, Gao ZL. Allogeneic bone marrow-derived mesenchymal stromal cells for hepatitis B virus-related acute-on-chronic liver failure: A randomized controlled trial.